相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
A Novel Method of Transcriptional Response Analysis to Facilitate Drug Repositioning for Cancer Therapy
Guangxu Jin et al.
CANCER RESEARCH (2012)
Peroxiredoxins 3 and 4 Are Overexpressed in Prostate Cancer Tissue and Affect the Proliferation of Prostate Cancer Cells in Vitro
Ramesh Ummanni et al.
JOURNAL OF PROTEOME RESEARCH (2012)
Proteomic Profiling of Germ Cell Cancer Cells Treated with Aaptamine, a Marine Alkaloid with Antiproliferative Activity
Sergey A. Dyshlovoy et al.
JOURNAL OF PROTEOME RESEARCH (2012)
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani et al.
NATURE BIOTECHNOLOGY (2012)
Expression of Eukaryotic Initiation Factor 5A and Hypusine Forming Enzymes in Glioblastoma Patient Samples: Implications for New Targeted Therapies
Michael Preukschas et al.
PLOS ONE (2012)
Predicting drug side-effect profiles: a chemical fragment-based approach
Edouard Pauwels et al.
BMC BIOINFORMATICS (2011)
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
Thomas O'Hare et al.
CLINICAL CANCER RESEARCH (2011)
An Algorithmic Framework for Predicting Side Effects of Drugs
Nir Atias et al.
JOURNAL OF COMPUTATIONAL BIOLOGY (2011)
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Identification of Candidate Small-Molecule Therapeutics to Cancer by Gene-Signature Perturbation in Connectivity Mapping
Darragh G. McArt et al.
PLOS ONE (2011)
Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform
Ramesh Ummanni et al.
PLOS ONE (2011)
Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data
Marina Sirota et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data
Xing-Ming Zhao et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
Transglutaminase 2: a multi-functional protein in multiple subcellular compartments
Donghyun Park et al.
AMINO ACIDS (2010)
The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway
Christian Preisinger et al.
CELLULAR SIGNALLING (2010)
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Guoqing Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors
Susanne B. Breitkopf et al.
JOURNAL OF PROTEOME RESEARCH (2010)
Mass spectrometry in high-throughput proteomics: ready for the big time
Tommy Nilsson et al.
NATURE METHODS (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling
Martin Peifer et al.
PLOS ONE (2010)
Predictive Mesoscale Network Model of Cell Fate Decisions during C. elegans Embryogenesis
David A. Winkler et al.
ARTIFICIAL LIFE (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Charting the molecular network of the drug target Bcr-Abl
Marc Brehme et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia
Gunhild Keller et al.
EXPERT REVIEW OF HEMATOLOGY (2009)
Identifying Drug Effects via Pathway Alterations using an Integer Linear Programming Optimization Formulation on Phosphoproteomic Data
Alexander Mitsos et al.
PLOS COMPUTATIONAL BIOLOGY (2009)
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Artur Gontarewicz et al.
BLOOD (2008)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
Local identification of scalar hybrid models with tree structure
Bernold Fiedler et al.
IMA JOURNAL OF APPLIED MATHEMATICS (2008)
Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Petra Ross-Macdonald et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A modular approach for integrative analysis of large-scale gene-expression and drug-response data
Zoltan Kutalik et al.
NATURE BIOTECHNOLOGY (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia
Alfonso Quintas-Cardama et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Crystal structure of the T315l Abl mutant in complex with the aurora kinases inhibitor PHA-739358
Michele Modugno et al.
CANCER RESEARCH (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Hypusination of eukaryotic imtiation factor 5A (eIF5A):: a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach
Stefan Balabanov et al.
BLOOD (2007)
Chemical combination effects predict connectivity in biological systems
Joseph Lehar et al.
MOLECULAR SYSTEMS BIOLOGY (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease
Justin Lamb et al.
SCIENCE (2006)
Systems biology and combination therapy in the quest for clinical efficacy
Jonathan B. Fitzgerald et al.
NATURE CHEMICAL BIOLOGY (2006)
Mechanisms of drug inhibition of signalling molecules
Judith S. Sebolt-Leopold et al.
NATURE (2006)
The mode-of-action by network identification (MNI) algorithm: a network biology approach for molecular target identification
Heming Xing et al.
NATURE PROTOCOLS (2006)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Chemogenomic profiling on a genomewide scale using reverse-engineered gene networks
D di Bernardo et al.
NATURE BIOTECHNOLOGY (2005)
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells
F Guo et al.
BLOOD (2005)
A computational algebra approach to the reverse engineering of gene regulatory networks
R Laubenbacher et al.
JOURNAL OF THEORETICAL BIOLOGY (2004)
Inferring genetic networks and identifying compound mode of action via expression profiling
TS Gardner et al.
SCIENCE (2003)
The specificities of protein kinase inhibitors: an update
J Bain et al.
BIOCHEMICAL JOURNAL (2003)
Issues and progress with protein kinase inhibitors for cancer treatment
J Dancey et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Functional discovery via a compendium of expression profiles
TR Hughes et al.
CELL (2000)
分享论文
